P2-IMU-838-PMS - Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis (Calliper)
Phase 2 – studying effectiveness and dosage
Conditions:
Progressive forms of Multiple Sclerosis
Sponsor: Immunic AG
trial.available_in:
БГ
Overview
Trial status: Authorised
Time to 24-week confirmed disability worsening as assessed on a composite of EDSS, 9-Hole Peg Test (9-HPT), or Timed 25-foot Walk (T25-FW) (24wCDW-Comp) during the MT period
Annualized rate of percent brain volume change (PBVC) during MT period.
Description
Time to 24-week confirmed disability worsening as assessed on a composite of EDSS, 9-Hole Peg Test (9-HPT), or Timed 25-foot Walk (T25-FW) (24wCDW-Comp) during the MT period
Who can participate
Age group: 18-64 years
Gender: Female, Male
Target enrollment: 230 participants
БГ